MBD Medical & Bio Decision

Professional company for 3D cell culture platform specialized in anticancer drug sensitivity and efficacy/toxicity test.

MBD provides a platform to predict the efficacy and toxicity of drugs based on the unique three-dimensional cell culture.

3D cell culture chip developed by MBD is a technology that overcomes the existing 2D cell culture problem and provides platform service to find the best anticancer drug using cancer cells derived from patients. We are continuing our research in cooperation with domestic and global pharmaceutical companies, hospitals and research institutes.

MBD will secure market competitiveness through a three-dimensional cell culture platform, which will provide economic benefits by shortening development time and minimizing the cost for new drug development companies, as well as reducing the economic cost for the patient family and provide hope to patients.

Based on honest business ethics that respects human life, we will grow into a global biotechnology company by conducting diverse and competitive R&D in the global market.

Founded originally in 2015 in South Korea, the company has grown into a successful international medical technology company with activities in Asia and USA and is currently growing actively in Europe.

MBD has secured the following international standards:

• CE Marking for the European market
• FDA clearance for the United States
• ISO 13485:2016 - Quality management for medical devices
• ISO/TC 229-TR 22455 - Nanotechnologies and advanced materials standards